If you typed Ascend CRO, Ascend Clinical, or Australia device CRO into a search box, you are usually comparing a new Australia–New Zealand–Asia medical-device shop with a first-in-human specialist that already runs Latin America from a Miami desk. That is a real shortlist. It is not the same product twice.
Ascend Clinical (public brand Ascend CRO, ascendcro.com) is a device-only CRO. The live site, retrieved 23 August 2026, is an Australia-based operation with CRC coverage claimed across Australia, New Zealand, and Asia. Competitive research compiled the same day dates the firm to 2024 and describes it as female-founded/led. The homepage does not print a founding year. What it does print is seniority: “nearly 40 years of experience serving leaders in medical device technology” and “more than three decades of clinical field experience” on the leadership page. Those sentences describe team tenure, not the age of the company. Do not confuse the two when you diligence the shop.
This is a practitioner comparison, not a teardown. Named sponsors are not on the public site. No named first-in-human press release was found. Company claims stay labeled as claims.
What Ascend CRO publishes
The homepage positions Ascend as “Your Australia-Based CRO for Clinical Research” and, more tightly, as a medical-device CRO. Copy covers FDA, European CE mark, HREC submissions, site and PI selection, monitoring, data management and biostatistics, DSMB and CEC services, clinical monitoring, and field support. Therapeutic areas listed: gastroenterology, cardiovascular, gynecology, orthopedics, bariatrics, endocrinology, and robotics. That is a hospital-device list, not a healthy-volunteer Phase I unit.
A New South Wales phone line is published: +61 2 8875 7898. The exact city is not emphasised. An info@ address sits in the footer. We will not harvest or reprint contact emails here.
Leadership published on ascendcro.com/leadership:
- Jules Bligh — Operations Director. The page credits more than two decades of clinical-research operations and specialisation in first-in-human and Phase I–IV trials, including prior leadership at CSIRO on diagnostics and biotech teams.
- Christine Nimalasiri — Clinical Director. More than 20 years managing medical-device trials across Asia-Pacific, with cardiology, neurology, and endocrinology named. The page also notes a panel role with the Australian Diabetes Clinical Trials Network (ADCTN).
- Peter Hanrahan — Field Services / Clinical Field Support Director. More than 30 years in medical devices across strategics, sites, and CROs; cardiology, vascular, and neurology are named.
Competitive mapping also lists Damien Woods as a co-founder on LinkedIn. That name was not on the leadership page fetched for this article. Treat it as a LinkedIn-attributed fact, not a homepage bio.
No named sponsor, protocol, or device FIH announcement appears on the pages reviewed. Public content is capability, therapeutic-area tiles, and events language. That is not a smear. It is what a 2024 shop looks like when the website is still a capability deck.
Where a lean Australia device CRO is the right tool
Hire a shop like Ascend when the protocol is an ANZ (or ANZ-plus-Asia) hospital device study, you want a device-only team rather than a drug Phase I unit, and you are willing to be an early client of a new firm whose public proof is people, not a named EFS-to-pivotal case. Field support is explicitly on the menu. That matters for implants and interventional work.
Do not hire it as a substitute for the country decision. Australia still sells CTN, English HREC packets, and — if you form an eligible company — a refundable R&D tax offset. Those are country features, not Ascend features. The established Australia EFS boutique with a public mitral-valve EFS-to-pivotal story is Mobius Medical. Ascend is the newer, smaller device-only alternative on the same geography slide.
Australia cash is not a 43.5% price cut
We will not invent a second rebate table. The country math is already published on bioaccess® vs Australia and The Australian R&D Rebate Math, Honestly, and it is the same math we used on the Mobius pillar. Facts we will not move:
- On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX).
- A fully captured 43.5% refundable R&D tax offset for groups under A$20 million aggregated turnover narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
- Capture is conditional: R&D generally through an eligible Australian company (the A$20 million threshold counts a U.S. parent). You fund the gross now; cash returns after year-end lodgement. Rebate-advance financing exists and has a cost.
- End-to-end start-up is broadly comparable once Australian site governance is included. CTN is not the whole clock. HREC plus site-by-site governance is.
Ascend can file HREC and run ANZ sites. That is trial conduct. It is not automatically rebate eligibility. A three-to-five-person U.S. team that wants 43.5% still generally forms an Australian company and pays advisers. bioaccess® contracts and starts in Latin America with no foreign subsidiary.
What bioaccess® is selling instead
bioaccess® is The First-in-Human CRO. Co-founded in 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). Legal entity IMH ASSETS CORP. Headquarters at 1200 Brickell Ave, Suite 1950 #1034, Miami. Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only focus since 2010. U.S. regulatory anchoring plus Latin American execution. ISO 14155 for devices. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (company about page).
Colombia is current operations, not nostalgia. As of 23 August 2026, Julio G. Martinez-Clark confirmed: bioaccess® still runs clinical trials in Colombia, keeps a local Colombian entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. INVIMA is a PAHO/WHO Level 4 authority. We do not tell sponsors to take new first-in-human work out of the country. See CRO in Colombia.
The product a U.S. device FIH actually buys is a small-n implant or interventional series, designed against a Pre-Sub / IDE / 21 CFR 812.28 conversation, imported into one or two hospitals, monitored in English, and overseen on U.S. Eastern time. That is not “ANZ CRC coverage plus a 2024 website.” It is a sixteen-year operating system with local entities.
Ascend CRO vs bioaccess® — device FIH comparison
| Dimension | Ascend Clinical / Ascend CRO | bioaccess® |
|---|---|---|
| Public age | Company: 2024 (competitive map). Site emphasises decades of team experience, not firm age | Founded 2010; ~16 years of CRO work |
| Home geography | Australia-based; ANZ + Asia CRC coverage claimed | Miami HQ; local LATAM entities including Colombia |
| Mix | Medical device only | FIH/EFS devices (also biopharma / radiopharma FIH) |
| Named device FIH / sponsors | None on public site | FIH/EFS is the core published product; case studies on bioaccessla.com |
| Leadership (site) | Jules Bligh; Christine Nimalasiri; Peter Hanrahan. Damien Woods listed as co-founder on LinkedIn, not on the fetched leadership page | Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill, Medical Director |
| Public device proof | Capability + events language | 30+ historical FIH device studies; 50+ FIH/EFS supported (company about page) |
| Gross cash | Australia cost base; rebate only with an eligible AU entity | ~35–45% below Australia on gross, program experience |
| FDA foreign data | ISO 14155 / FDA-and-CE language on the site; FDA decides case by case | ISO 14155 → 21 CFR 812.28 (FDA decides) |
| Colombia | Not a Colombia CRO | Still executing; local entity; INVIMA in-country |
How to keep Ascend on the list without confusing the job
If the protocol belongs in ANZ hospitals, English end-to-end is non-negotiable, and an Australian entity is already in the legal workplan, put Ascend next to Mobius and Australian Healthcare Solutions — and ask for a named or de-identified device EFS: class, implant versus non-implant, n, ISO 14155 monitoring plan, English TMF, and FDA-file use. If that package exists, the firm can be the ANZ prime. If it does not, do not learn that after first patient in.
If the number that matters is gross cash this quarter, you will not stand up an Australian company, or you want U.S. time-zone oversight and Latin American surgical volume — including Colombia when that is the right INVIMA file — put bioaccess® in the prime column. Request a proposal at contact.
ISO 14155 and 21 CFR 812.28 are geography-neutral. Acceptance is FDA’s, case by case. It is not awarded because the trial ran under CTN, and it is not denied because it ran under INVIMA or ANVISA.
FAQ — Ascend CRO Australia and device FIH
Is Ascend CRO a first-in-human device CRO?
The leadership page credits Jules Bligh with first-in-human and Phase I–IV experience. The firm is medical-device only. The public site does not name a sponsor or an FIH protocol. FIH is claimed in people copy, not evidenced with a case study.
When was Ascend founded?
Competitive research compiled 23 August 2026 dates the company to 2024. The live homepage talks about decades of team experience. Ask the firm for the incorporation year in writing if the board cares about vintage.
Is Ascend the same as Mobius?
No. Both are Australian device specialists. Mobius (2008) publishes an EFS-to-pivotal mitral story and a named CT.gov sponsorship. Ascend is newer and smaller. See the Mobius pillar.
Is Australia cheaper than Latin America after the R&D tax incentive?
Only if you fully capture 43.5% through an eligible Australian company and fund the higher gross while you wait. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience. Details on the rebate math post.
Does bioaccess® still run first-in-human trials in Colombia?
Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.
Competitor facts from ascendcro.com and /leadership, 23 August 2026. Founding year from competitive map. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.